Review Decision - October 2009

Review of NICE Technology Appraisal Guidance No 110: Rituximab for the treatment of follicular lymphoma 

Review decision 

The Institute was proposing that it is appropriate to update the guidance.

During consultation, the majority of comments received by the Institute agreed with the proposal put forward.  After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal. We will therefore update the guidance, to include the extension to the license (covering a wider range of chemotherapy regimens).

The review will be planned into the appraisal work programme at the earliest availability and inform you of the dates in due course.

October 2009

 

This page was last updated: 30 December 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.